Evidence map›Paper›PMID 32169854›Full record

ArticleThe Journal of biological chemistry2020

A potential new target for autoinflammatory bone disease.

Elizabeth L Hartland

Open access · hybridAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Impact of the Host-Microbiome on Osteomyelitis Pathogenesis.Frontiers in molecular biosciences · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Elizabeth L HartlandCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research and Department of Molecular and Translational Science, Monash University, Clayton, Victoria 3168, Australia. Electronic address: elizabeth.hartland@hudson.org.au.
Hudson Institute of Medical Research · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic recurrent multifocal osteomyelitis (CRMO) is an autoinflammatory bone disease mediated by the inflammatory cytokine, IL-1β. Although IL-1β is known as the key driver of bone lesions in CRMO, the signaling events leading to pathogenic levels of the cytokine are not fully understood. Using a genetic mouse model of CRMO, Dasari

Indexed as

InflammasomesOsteomyelitisAnimalsCaspase 8MiceNLR Family, Pyrin Domain-Containing 3 ProteinProtein-Tyrosine KinasesSyk KinaseCaspase 8InflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseProtein-Tyrosine KinasesSyk KinaseSyk protein, mouse

Identifiers

PMID32169854
PMCPMC7076201
OpenAlexW3011910205

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.